Halozyme Therapeutics

Halozyme Therapeutics

Yahoo Finance • 6 days ago

Halozyme Therapeutics (HALO) Expands Argenx Deal, Is It Still 27% Below Fair Value?

Halozyme's argenx expansion puts ENHANZE back in focus Halozyme Therapeutics (HALO) extended its ENHANZE collaboration with argenx to cover two more exclusive targets, taking the total to eight and adding fresh attention to the stock's pa... Full story

Yahoo Finance • 7 days ago

Is Halozyme’s EU Injunction on Subcutaneous Keytruda Reshaping the Investment Case For Merck (MRK)?

In late September 2026, a Dutch court ruled in favor of Halozyme Therapeutics, issuing an injunction that halts manufacture and sale of Merck's subcutaneous Keytruda in eight European countries following a patent dispute. This setback affe... Full story

Yahoo Finance • 7 days ago

Sector Update: Healthcare Stocks Rise in Afternoon Trading

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 1.6% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 7 days ago

Halozyme stock rises after winning injunction against Merck

Investing.com --Halozyme Therapeutics Inc (NASDAQ:HALO) shares rose 2% Wednesday after the company won a patent infringement injunction against Merck's Keytruda SC in multiple European markets. Before you buy NVIDIA: our AI model's stock... Full story

Yahoo Finance • 22 days ago

1 Cash-Producing Stock to Target This Week and 2 We Question

1 Cash-Producing Stock to Target This Week and 2 We Question Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to... Full story

Yahoo Finance • 23 days ago

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech firms have been increasingly directing capital toward oncology therapeutics in recent years, reflecting a structural shift as companies recognize the significant commercial potential of precision oncology. According to BioPharma Di... Full story

Yahoo Finance • 26 days ago

Halozyme prices $1.3B convertible senior notes offering due 2033

* Halozyme Therapeutics (HALO [https://seekingalpha.com/symbol/HALO]) on Thursday announced the pricing of $1.3B aggregate principal amount of 1.50% convertible senior notes due 2033. * The offering size was increased from the previou... Full story

Yahoo Finance • 29 days ago

4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike Fears

The U.S. economy is entering a more challenging environment as renewed Middle East tensions push oil prices above $100 a barrel, adding to inflationary pressures. Annual CPI inflation accelerated to 3.4% in August, well above the Federal R... Full story

Yahoo Finance • last month

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks

Q2 Rundown: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs Other Therapeutics Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:... Full story

Yahoo Finance • last month

Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?

Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) offers broad healthcare exposure at a fraction of the cost, while First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) provides an aggressive, concentrated focus on biotechnology i... Full story

Yahoo Finance • last month

Is Invesco S&P MidCap 400 Pure Growth ETF (RFG) a Strong ETF Right Now?

Making its debut on 03/01/2006, smart beta exchange traded fund Invesco S&P MidCap 400 Pure Growth ETF (RFG) provides investors broad exposure to the Style Box - Mid Cap Growth category of the market. What Are Smart Beta ETFs? Products t... Full story

Yahoo Finance • last month

1 Mid-Cap Stock on Our Watchlist and 2 We Avoid

1 Mid-Cap Stock on Our Watchlist and 2 We Avoid Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competitio... Full story

Yahoo Finance • last month

Halozyme to Participate at Upcoming Investor Conferences

SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to... Full story

Yahoo Finance • last month

Ten healthcare stocks leading in year-over-year CapEx growth

[Health Care Medical Stock Market Industry Sector Wall Street Buildings 3d Illustration] iQoncept/iStock via Getty Images With the second-quarter earnings season now largely behind us, investors are turning their attention to how healthca... Full story

Yahoo Finance • 2 months ago

1 Healthcare Stock with Exciting Potential and 2 We Avoid

1 Healthcare Stock with Exciting Potential and 2 We Avoid Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as h... Full story

Yahoo Finance • 2 months ago

Biotech Breakout: What's in focus after Moderna's cancer win?

[mRNA or messenger RNA. The concept of mRNA vaccine. Innovative methods to treat virus. 3d render] Krot Studio INVESTORS SHOULD KNOW: A major Phase 3 trial win from Moderna (MRNA [https://seekingalpha.com/symbol/MRNA]) and Merck (MRK [htt... Full story

Yahoo Finance • 2 months ago

2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges

2 Mid-Cap Stocks with Solid Fundamentals and 1 Facing Challenges Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face i... Full story

Yahoo Finance • 2 months ago

XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?

The State Street SPDR S&P Biotech ETF (NYSEMKT:XBI) provides broad exposure to the biotech industry, while the First Trust NYSE Arca Biotechnology Index Fund (NYSEMKT:FBT) offers a much more concentrated, equal-weighted alternative. Biote... Full story

Yahoo Finance • 2 months ago

Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE

(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results. Halozyme Therapeutics Inc. (HALO) Halozyme is a biopharmaceutical... Full story

Yahoo Finance • 3 months ago

State Street vs. First Trust: Is a Broad Healthcare or Biotech Focus Better for Your Portfolio?

Key Points State Street Health Care Select Sector SPDR ETF offers a significantly lower expense ratio of 0.08% compared to the 0.55% charged by First Trust NYSE Arca Biotechnology Index Fund. First Trust's fund focuses exclusively on 30 b... Full story